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The scope of functional heterogeneity in macrophages has been defined by two polarized
end states known as M1 and M2, which exhibit the proinflammatory activities necessary
for host defense and the tissue repair activities required for restoration of homeostasis,
respectively. Macrophage populations in different tissue locations exist in distinct pheno-
typic states across this M1/M2 spectrum and the development and abundance of individual
subsets result from the local and systemic action of myeloid colony-stimulating factors
(CSFs) including M-CSF and GM-CSF.These factors have relatively non-overlapping roles in
the differentiation and maintenance of specific macrophage subsets. Furthermore, there is
now evidence that CSFs may also regulate macrophage phenotype during challenge. Cell
culture studies from multiple laboratories demonstrate that macrophages developed in
the presence of GM-CSF exhibit amplified response to M1 polarizing stimuli while M-CSF
potentiates responses to M2 stimuli. As a consequence, these factors can be important
determinants of the magnitude and duration of both acute and chronic inflammatory pathol-
ogy and may, therefore, be potential targets for therapeutic manipulation in specific human
disease settings.
Keywords: macrophage activation, macrophage colony-stimulating factor, granulocyte macrophage colony-
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THE MACROPHAGE POLARIZATION PARADIGM: CLASSICAL
(M1) AND ALTERNATIVE (M2) ACTIVATION PHENOTYPES
The mononuclear phagocyte system is known to exhibit substan-
tial functional heterogeneity (1–3). Though the scope of such
heterogeneity is dramatically large, the prevailing concept of het-
erogeneity is organized around two polarized endpoints known as
classical and alternative activation, also often termed M1 and M2,
respectively (4–6). These polarized states represent the capacities
to initiate inflammatory response, carry out anti-microbial func-
tion, and promote Th1/Th17 adaptive immune responses for M1,
or, for M2, to phagocytize debris, promote wound healing, antag-
onize destructive inflammation, and suppress adaptive immunity.
These functional activities are mediated by molecular features that
include, for M1, the production of proinflammatory cytokines,
co-stimulatory molecules including CD80/86, effector enzymes
such as iNOS, and NADPH oxidase or, for M2, anti-inflammatory
cytokines, immunosuppressive arginase, and scavenger receptors
(CD163) (5, 6).
Importantly, there are multiple subsets of macrophages with
relatively non-overlapping functional responsibilities and this
additional heterogeneity must be superimposed upon the M1/M2
paradigm (2, 7–9). Resident macrophage populations exhibit
many common features but are not identical, often deriving
from distinct origins and showing a broad spectrum of func-
tional potential (10). It is noteworthy that most resident tissue
macrophages are capable of self-replenishment and generally do
not derive from circulating monocytes (9, 11). There are two major
categories of monocytes found in the circulation. In the mouse,
these are characterized as Ly6C-hi/CCR2hi and Ly6Clo/CX3CR1hi.
The former is likely the source of most infiltrating inflammatory
macrophages or dendritic cells, while the latter is a patrolling and
longer lived cell population that provides maintenance of the vas-
cular endothelium (7). The understanding of macrophage subsets
and their developmental origin has advanced dramatically through
the application of fate mapping and other transgenic strategies
(2, 11–13). Moreover, the molecular features responsible for dis-
tinct functional activities (anti-microbial, inflammatory, repara-
tive, etc.) have been defined through detailed analysis of isolated
cell populations and cell type-specific transgenic manipulation (5,
6, 14). These macrophage subpopulations exhibit many molecular
similarities that reflect their common myeloid origin but each has
very distinct responsibilities and their inter-conversion appears to
be limited under steady-state conditions (9). Moreover, each of
these subset populations can be induced to exhibit M1 or M2 like
functional polarization.
The concepts of classical and alternative activation or even M1
and M2 markedly oversimplify the spectrum of macrophage phe-
notypes that exist within vertebrate organisms (6, 15). The number
of individual phenotypes will, in part, depend upon the num-
ber of gene products that are measured and the degree to which
gene expression events are independent (16). Furthermore, the
spectrum of environmental cues encountered by macrophages is
highly complex both in number and exposure sequence. Hence,
the combinatorial spectrum of possible phenotypes is extremely
large. As a simplifying principle, the number of specific molecu-
lar endpoints used to define phenotype can be limited to those
activities and molecules requisite to the functions of interest (e.g.,
anti-microbial, reparative, etc.). This will enable comparison of
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macrophage populations within different physiologic and patho-
logic circumstances and evaluation of how the specific mol-
ecular characteristics may vary with cell subset and stimulus
environment.
Finally, it is also important to recognize that inflammation is a
dynamic process that is well recognized to proceed in stages with an
early proinflammatory function followed by a transition to heal-
ing and restoration of tissue homeostasis (1, 17, 18). While this
process includes the temporally distinct recruitment of multiple
cell populations that can provide different aspects of the evolving
functional features, there is also reason to believe that infiltrat-
ing inflammatory monocytes may cycle through different states of
functional activity that are, at a minimum, reminiscent of the M1
and M2 categories (19, 20).
REGULATION OF POLARIZATION
Classically and alternatively activated (M1 or M2) macrophage
phenotypes are defined by the specific molecular characteristics
induced in response to prototypic pro- and anti-inflammatory
stimuli [e.g., IFNγ, Toll-like receptor (TLR) agonists, IL-4/IL-
13, IL-10, etc.] (5, 15, 18). Such molecular correlates are now
used with increasing frequency to identify populations of M1
or M2 like macrophages in different physiologic settings. Thus,
M1 macrophages express high levels of IL-12 or IL-23, TNFα,
IL-1α/β, chemokines eliciting neutrophil, inflammatory mono-
cyte, and proinflammatory T lymphocyte infiltration (CXCL1-3,
8, CCL2, CXCL9, and CXCL10), CD80/86, CD64, MARCO, iNOS,
and reactive oxygen species (hydroxyl radicals and H2O2) induced
by M1 polarizing stimuli. Correlates of the M2 phenotype include
IL-10, TGFβ, arginase, YM1, FIZZ1 (in the mouse), the man-
nose receptor (CD206), and scavenger receptors, such as CD163
induced following exposure to IL-4, IL-13, TGFβ, IL-10, and other
agents.
In this context, M1 and M2 phenotypes are often presented as
relating to the actions of Th1 and Th2 cell subsets, respectively,
because of the Th1 and Th2 lymphokine-based modulation of
their defining features (15, 21). It is evident, however, that polar-
ized macrophage function existed prior to the development of
adaptive immunity in evolution (22, 23). Moreover, mice with
T- and B-cell deficiency still possess the potential for polarized
function demonstrating that the M1 and M2 concept can exist
in the absence of adaptive immunity and its products (4). Nev-
ertheless, the normal vertebrate immune system operates with
a full spectrum of immune cell populations and their products
clearly influence the macrophage polarization process. Indeed, it
is likely that macrophages will encounter both M1 and M2 polar-
izing stimuli simultaneously within the inflamed tissue microen-
vironment. The complexity of response to this may reasonably
explain the large spectrum of macrophage phenotypes encoun-
tered in cell populations in vivo and the variability in markers of
polarization.
Macrophage populations may also exhibit a predisposition for
polarization toward the M1 or M2 phenotype. For example, dif-
ferent strains of mice and rats have been shown to have skewed
patterns of activation potential that ultimately correlate with their
innate and adaptive immune functionality (4, 24, 25). Further-
more, it is well recognized that macrophages in different anatomic
or physiologic settings exhibit dramatically different capacities for
polarization. Importantly, there are agents that, by themselves, do
not induce expression of common polarization markers but which
can alter response to stimulation with classical M1 or M2 stimuli.
Because most, if not all macrophage populations, can respond to
either M1 or M2 stimuli, the tone of a response may be set by
differential regulation of sensitivity to polarizing stimuli. Hence,
agents that promote priming of macrophages for enhanced or
diminished response to classical or alternative activation are likely
to be important determinants of the character and temporal pat-
terns of macrophage functional change in the course of response
to injury and infection.
The myeloid colony-stimulating factors (CSFs) M-CSF and
GM-CSF are known to modulate macrophage phenotype (26, 27).
While both agents were first identified as inducers of myeloid cell
differentiation and proliferation in cultured bone marrow prog-
enitors, many studies illustrate their importance in the magnitude,
duration, and character of many forms of inflammatory response
(26–30). Though GM-CSF is associated with classical or M1 acti-
vation while M-CSF is linked with alternative or M2 activation,
neither factor is a potent stimulus of definitive polarization mark-
ers, when compared with prototypic polarizing stimuli (e.g., IFNγ,
TLRs, IL-4, IL-10, etc.) (31–33). Instead, GM-CSF and M-CSF
appear to induce a state in which macrophages are primed for M1
and M2 endpoints, respectively.
MOLECULAR AND CELLULAR PHENOTYPES PRODUCED BY
M-CSF AND GM-CSF IN VITRO
While receptor signaling mechanisms mediating responses to M-
CSF and GM-CSF are appreciated in basic detail (5, 6, 26),
understanding of how these agents modulate functional polar-
ization remains obscure. The potential for CSFs to regulate the
responses of mature myeloid cell populations is well recognized.
For example, the capacity of GM-CSF, but not M-CSF, to gen-
erate DCs in culture clearly demonstrated distinct functional
roles (34). Verreck et al. initially demonstrated that GM-CSF or
M-CSF treatment of myeloid cells in culture was able to selec-
tively alter the magnitude of M1 or M2 polarized phenotypes
following appropriate stimulation (31, 32). While GM-CSF cul-
tured macrophages stimulated with LPS± IFNγ produced large
amounts of IL-23 or IL-12 and little IL-10, M-CSF cultured
macrophages were unable to generate either IL-12 or IL-23 but
did produce significant amounts of IL-10 under the same con-
ditions. GM-CSF-treated cells produced appreciably higher levels
of other proinflammatory cytokines including TNF, IL-18, IL-1β,
and IL-6 in comparison to those grown in M-CSF. Furthermore,
M-CSF-treated cells were more phagocytic but less competent in
antigen presentation when compared with GM-CSF treated cells.
For the most part, the growth factor-treated cells did not exhibit
the full M1 or M2 phenotypes in otherwise unstimulated state but
rather showed polarized sensitivity for corresponding response
to IFNγ/TLR signaling. These findings led the authors to con-
clude that GM-CSF and M-CSF were promoting the development
of monocyte-macrophages predisposed to exhibit differential M1
and M2 phenotypes, respectively. These findings were confirmed
and extended by Fleetwood et al. using bone marrow derived
macrophages from mice cultured in either GM-CSF or M-CSF
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(33). Interestingly, though GM-CSF is frequently used to generate
DCs from bone marrow progenitors, the cells arising from such
cultures more closely resemble macrophages than dendritic cells
based upon whole genome profiling (35). Though there are many
similarities between human being and mouse macrophages in dif-
ferent polarized states, there also appear to be many differences
(14, 35–37). Despite these findings, there remain important ques-
tions about the strict relationship between these two factors and
the molecular/functional phenotype definitions for M1 and M2.
Thus, studies in both mouse and human cells show that the effects
of GM-CSF and M-CSF on gene expression do not map exactly
with M1 and M2 marker expression, even following stimulation
(35, 38, 39).
In the context of the hypothesis that macrophage predisposition
is an important determinant of polarized phenotype expression,
there are certainly other natural ligands that have the capacity to
alter macrophage sensitivity to specific polarization stimuli (40–
45). Because inflammatory responses in vivo will always occur in a
complex stimulus environment, these additional agents are likely
to co-operate with or antagonize the actions of the CSFs. PPARγ,
in particular, has been reported to be required for development
of alternatively activated macrophages in the context of insulin
resistance and metabolic inflammatory disease (46). The tyrosine
kinase receptor CD136 (RON, MST1R) can also modulate sensitiv-
ity for M2-like activators, in part by altering the sensitivity to TLR
stimulation (24, 47). In contrast to these agents, NOTCH and its
ligand RBP-J, are reported to promote M1-like responses via alter-
ations in intracellular signaling factors including IRF8 and SOCS3
(40). Indeed, the sensitivity of myeloid cell populations to polar-
izing stimuli appears to be controlled in part by alterations in the
abundance or activity of the signaling pathway components that
mediate responses to pro- and anti-inflammatory stimuli (41–44,
48–50). Thus, signaling adaptors, protein kinases, protein phos-
phatases, and transcription factors including members of the IRF,
SOCS, Tec, and KLF families have all been implicated in control-
ling either M1 or M2 polarization. The mechanisms through which
stimulus sensitivity is altered by ligand/receptor pairs, such as the
CSFs, as well as others mentioned above remains to be fully eluci-
dated but intracellular signaling factors are likely to be important
targets.
ROLE OF M-CSF AND GM-CSF IN MACROPHAGE
FUNCTIONAL POLARIZATION IN VIVO
M-CSF and GM-CSF have distinct effects on the development and
expansion of myeloid cell populations in different anatomic set-
tings (26, 27). Based upon studies of mice with targeted deletion
of ligand and/or receptor genes, M-CSF is known to be required
for the production and maintenance of many (though not all)
tissue macrophage populations (51). In this regard, distinctions
between receptor and ligand deficient mice revealed the existence
of a second ligand (IL-34), which is now known to be necessary
for the maintenance of a subset of tissue macrophage populations
(microglia and Langerhans cells) (52). M-CSF and IL-34 func-
tion in homeostatic maintenance of tissue-resident macrophage
populations through promoting viability and proliferation and
both drive predisposition to M2 character (53). While M-CSF
is found in the serum of healthy individuals and can be pro-
duced constitutively by epithelia, fibroblasts, endothelial cells, and
by macrophages themselves, its expression can be elevated by
inflammatory conditions in many cells including macrophages
as well as T and B lymphocytes (27). In contrast to M-CSF or
IL-34, GM-CSF deficiency has little impact on steady-state tis-
sue macrophage populations with the exception of those found in
the lung (26, 27). While GM-CSF is believed to be important for
the development of infiltrating inflammatory DCs, recent find-
ings show that M-CSF but not GM-CSF sensitivity is requisite for
these cell populations (13). Importantly, GM-CSF, unlike M-CSF,
is not detectable in most tissues at rest but expression is frequently
induced during inflammatory or immune stimulation in many
tissues and cell types (26, 27, 54).
While studies using animals with global or cell-type restricted
deficiencies in M-CSF or GM-CSF ligand/receptor function do
provide insight into their relative contributions to macrophage
phenotypes during inflammatory responses in vivo, the inter-
pretation of such experiments should be viewed with caution
due to the impact of such deficiencies on development and/or
abundance of specific myeloid subsets. These studies are effec-
tively complemented by transiently manipulating M- or GM-CSF
levels using specific ligand delivery or ligand/receptor antago-
nism. Results from multiple studies indicate that both M-CSF
and GM-CSF can modulate the magnitude and character of
inflammatory response in multiple tissue specific disease mod-
els (2, 26, 54–56). These include autoimmune encephalomyelitis
(MS), atherosclerosis, arthritis, nephritis, lung inflammation, and
cancer. In most cases, however, the mechanisms through which
these endpoints are achieved have not been elucidated. Certainly,
both factors have the capacity to promote survival and/or expan-
sion of macrophage populations both systemically and in spe-
cific tissue locations and the decreased number of macrophages
observed with CSF antagonism would likely result in reduced
intensity and/or duration of disease (26). Multiple approaches
including delivery of M-CSF, antibody-mediated depletion of
the ligand, antibody-induced antagonism of receptor, or the
use of receptor tyrosine kinase inhibitors have provided evi-
dence supporting both positive and inhibitory roles for M-CSF
in inflammatory diseases (26, 55). Interestingly, several recent
reports demonstrate that antagonistic targeting of M-CSF can
have appreciable benefit in tumor therapy as a consequence of
altering the tumor-associated macrophage phenotype from M2 to
M1 (49, 57–59).
There are several important considerations that can provide
some speculative insight into the role for these CSFs in regu-
lating the nature of macrophage polarization in vivo. First are
the patterns of CSF expression within tissues both at rest and
during inflammatory responses. While the expression of both
factors can be amplified during response to various forms of
tissue injury, it is apparent that M-CSF is produced constitu-
tively in many tissues and is critical for the maintenance of
resident tissue populations throughout the body. GM-CSF, in
contrast, is rarely detectable except at times of injury and does
not appear to be a critical determinant of macrophage num-
bers with a few exceptions (i.e., the lung). Second, resident
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macrophage populations are generally found to exhibit an M2-
like phenotype under resting conditions, consistent with the need
to minimize tissue damaging inflammatory reaction (10). This
is certainly consistent with the ability of M-CSF to predispose
toward an M2 phenotype in cell culture experiments involv-
ing both human monocytes and mouse bone marrow-derived
macrophages. Third, GM-CSF has been shown to be a critical
determinant of inflammatory injury in several model systems (60–
62). Particularly, T-cell derived GM-CSF was recently shown to
be critical for disease phenotype in experimental autoimmune
encephalomyelitis, generated by IL-23 action on Th17 cells (60,
61). In this instance, GM-CSF selectively targeted infiltrating
macrophages within the CNS. Finally, several studies examin-
ing responses to M-CSF and GM-CSF in vitro show that the
M1/M2 phenotype can be reversibly modulated by GM-CSF/M-
CSF exposure in cell culture and GM-CSF predisposition may be
dominant (33, 39, 63) (Hamilton, unpublished). This is also sup-
ported by increased bioavailability (half-life) of GM-CSF, which
might also contribute to its dominance relative to M-CSF. We
would suggest then that M-CSF provides the default condition
and will promote an M2 (healing) phenotype both at rest and in
the absence of other forms of stimulation. Induced expression of
GM-CSF (e.g., during adaptive T-cell driven immune responses)
will provide the mechanism for retaining or re-expressing an M1
phenotype when conditions require (e.g., continued infection or
injury). It is clear, however, that the specific effects of M-CSF
and GM-CSF on macrophage polarization in cell culture mod-
els are unlikely to fully predict their effects in vivo. This reflects
complexities associated with the variable nature of inflammatory
injury, stimulus exposure, and distinct features of specific tissue
microenvironments.
UNANSWERED QUESTIONS
Macrophage heterogeneity or phenotype polarization is an area
of high current interest and the impact of myeloid CSFs on this
process in vivo is evident but poorly understood. Hence, we pose
the following outstanding questions regarding the roles that M-
CSF and GM-CSF may play, particularly through modulating
sensitivity to M1 and M2 promoting stimuli with the expectation
that answers will help to clarify the process and provide insights
to therapeutic application. (1) What mechanisms are involved in
skewing responses to polarizing stimuli? Can we identify specific
CSF-induced patterns of gene expression that are requisite to gen-
erating macrophages predisposed for more potent responses to
cytokines and pattern recognition receptors? Can we correlate out-
comes obtained in vitro with those obtained in vivo? (2) What are
the sources and timing of M-CSF and GM-CSF expression within
specific tissues during different forms of inflammatory response?
Which myeloid cell populations are the targets of the CSFs and how
is this co-ordinated with the need to enhance or diminish specific
aspects of function over the full course of inflammatory response?
(3) Finally, we must begin to consider not only the mechanisms
through which M-CSF and GM-CSF operate but also how these
stimuli are integrated with the host of other agents encountered
within inflammatory settings that also have marked influence on
M1/M2 skewing?
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